1. Clinical & Scientific Overview
Lorazepam (Oral Tablets & Parenteral IV/IM Status Epilepticus) (TIP-MED-000210, Reference Code [11.6]) is classified under
CNS & Psychiatric Medicines (Ch 11) as a Intermediate-Acting 3-Hydroxy Benzodiazepine (Direct Phase-II Glucuronidation with ZERO Active Metabolites; Anxiolytic, Sedative & Anticonvulsant).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 11 [11.6], p. 142): Ativan (Pfizer), Lopez (Intas), Lorvan, Larpose (Cipla) — Strengths & Dosage Forms: Oral Uncoated Scored Tablets: 1 mg, 2 mg; Sublingual/MD Tablets: 0.5 mg, 1 mg, 2 mg; Parenteral Injection: 2 mg/mL (2 mL ampoule — keep refrigerated!)
Oral Uncoated Scored Tablets: 1 mg, 2 mg; Sublingual/MD Tablets: 0.5 mg, 1 mg, 2 mg; Parenteral Injection: 2 mg/mL (2 mL ampoule — keep refrigerated!)
3. Mechanism of Action & Pharmacodynamics
Intermediate-Acting 3-Hydroxy Benzodiazepine (Direct Phase-II Glucuronidation with ZERO Active Metabolites; Anxiolytic, Sedative & Anticonvulsant) acting on target receptor/enzyme pathways in CNS & Psychiatric Medicines (Ch 11): clinical efficacy is mediated via Intermediate-Acting 3-Hydroxy Benzodiazepine (Direct Phase-II Glucuronidation with ZERO Active Metabolites; Anxiolytic, Sedative & Anticonvulsant) for Acute severe anxiety and agitation; short-term insomnia associated with anxiety; pre-operative anaesthetic premedication; First-Line Parenteral Drug of Choice for Status Epilepticus (4 mg slow IV) and Acute Alcohol Withdrawal Syndrome / Delirium Tremens (preferred benzodiazepine in Liver Disease!); catatonia..
4. Therapeutic Indications & Evidence-Supported Uses
- Acute severe anxiety and agitation
- short-term insomnia associated with anxiety
- pre-operative anaesthetic premedication
- First-Line Parenteral Drug of Choice for Status Epilepticus (4 mg slow IV) and Acute Alcohol Withdrawal Syndrome / Delirium Tremens (preferred benzodiazepine in Liver Disease!)
- catatonia
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Anxiety: 0.5 mg to 1 mg two to three times daily. Insomnia due to anxiety: 1 mg to 2 mg at bedtime. In Elderly or Debilitated Patients: Start at 0.5 mg (half of a 1 mg tablet) at bedtime! Follow physician prescription. • Status Epilepticus First-Line IV: 0.1 mg/kg slow IV (<=2 mg/min, max 4 mg/dose; may repeat once after 10–15 min).
Administration & Meal Timing: With or without food. | At bedtime (30 min before sleep), or divided doses for severe acute anxiety.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Inactive glucuronide excreted in urine; use lower doses (0.5 mg) in severe CKD due to heightened CNS sensitivity. Hepatic: THE SAFEST BENZODIAZEPINE IN LIVER CIRRHOSIS AND THE ELDERLY (via Phase-II UGT preservation: the 'LOT' drugs—Lorazepam, Oxazepam, Temazepam)! Because Phase-II glucuronidation is preserved in cirrhosis and aging (unlike Phase-I CYP oxidation which fails in cirrhosis), Lorazepam does not accumulate active metabolites in liver disease (though use cautiously as any sedative can still precipitate hepatic encephalopathy in severe Child-Pugh C cirrhosis).
Renal: Inactive glucuronide excreted in urine; use lower doses (0.5 mg) in severe CKD due to heightened CNS sensitivity. Hepatic: THE SAFEST BENZODIAZEPINE IN LIVER CIRRHOSIS AND THE ELDERLY (via Phase-II UGT preservation: the 'LOT' drugs—Lorazepam, Oxazepam, Temazepam)! Because Phase-II glucuronidation is preserved in cirrhosis and aging (unlike Phase-I CYP oxidation which fails in cirrhosis), Lorazepam does not accumulate active metabolites in liver disease (though use cautiously as any sedative can still precipitate hepatic encephalopathy in severe Child-Pugh C cirrhosis).
Renal: Inactive glucuronide excreted in urine; use lower doses (0.5 mg) in severe CKD due to heightened CNS sensitivity. Hepatic: THE SAFEST BENZODIAZEPINE IN LIVER CIRRHOSIS AND THE ELDERLY (via Phase-II UGT preservation: the 'LOT' drugs—Lorazepam, Oxazepam, Temazepam)! Because Phase-II glucuronidation is preserved in cirrhosis and aging (unlike Phase-I CYP oxidation which fails in cirrhosis), Lorazepam does not accumulate active metabolites in liver disease (though use cautiously as any sedative can still precipitate hepatic encephalopathy in severe Child-Pugh C cirrhosis).
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in acute narrow-angle glaucoma, severe respiratory insufficiency, sleep apnoea, and myasthenia gravis. (Parenteral Lorazepam injection contains propylene glycol diluent—high-dose continuous IV infusions can cause propylene glycol lactic acidosis and acute kidney injury).
Key Clinical Precautions: Renal: Inactive glucuronide excreted in urine; use lower doses (0.5 mg) in severe CKD due to heightened CNS sensitivity. Hepatic: THE SAFEST BENZODIAZEPINE IN LIVER CIRRHOSIS AND THE ELDERLY (via Phase-II UGT preservation: the 'LOT' drugs—Lorazepam, Oxazepam, Temazepam)! Because Phase-II glucuronidation is preserved in cirrhosis and aging (unlike Phase-I CYP oxidation which fails in cirrhosis), Lorazepam does not accumulate active metabolites in liver disease (though use cautiously as any sedative can still precipitate hepatic encephalopathy in severe Child-Pugh C cirrhosis).
8. Adverse Effects Profile
- Sedation, drowsiness, dizziness, unsteady gait/ataxia, muscle weakness, anterograde amnesia.
- Falls and hip fractures in the elderly, respiratory depression (with opioids/alcohol), paradoxical agitation/delirium, dependence and withdrawal seizures on abrupt discontinuation.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Pharmacokinetic Advantage: Unlike Alprazolam, Diazepam, or Clonazepam, Lorazepam undergoes direct Phase-II hepatic UGT glucuronidation to an inactive glucuronide without using Phase-I CYP450 enzymes! Therefore, CYP3A4/CYP2C19 inhibitors (fluconazole, omeprazole, macrolides, diltiazem) do NOT inhibit Lorazepam clearance! However, Sodium Valproate and Probenecid inhibit UGT glucuronidation and double Lorazepam plasma levels (reduce Lorazepam dose by 50% if combined with Valproate!)
- Additive CNS/respiratory depression with opioids, pregabalin, clozapine, and alcohol
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: If a short-term benzodiazepine is strictly required in an elderly patient or a patient with liver disease, explain that a half-tablet (0.5 mg) of Ativan / Lopez at bedtime clears cleanly without leaving multi-day active break-down products in the body (unlike Diazepam or Clonazepam). Still enforce strict fall precautions when walking to the toilet at night, and taper off within 2–4 weeks.
- Meal & Clock Timing Instruction: With or without food. (At bedtime (30 min before sleep), or divided doses for severe acute anxiety.)
- Missed Dose Protocol: Skip if missed at bedtime; never take the next morning or double the dose.
- Geriatric Dispensing Pearl: While all benzodiazepines carry Beers Criteria fall/delirium warnings in the elderly, if a short course is clinically unavoidable, low-dose Lorazepam (0.5 mg) is pharmacologically safer than long-half-life Clonazepam or Diazepam because its half-life (10–14 h) and Phase-II clearance do not change with age.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated Scored Tablets: 1 mg, 2 mg; Sublingual/MD Tablets: 0.5 mg, 1 mg, 2 mg; Parenteral Injection: 2 mg/mL (2 mL ampoule — keep refrigerated!)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 11 [11.6] (p. 142)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.18]-C138 Desvenlafaxine Succinate — Serotonin–Noradrenaline Reuptake Inhibitors (SNRIs)
- [11.19]-CMP139 Fluvoxamine Maleate IP — Selective Serotonin Reuptake Inhibitor (SSRI with Mild Anticholin
- [11.21]-CMP140 Bupropion Hydrochloride SR/XL IP — Noradrenergic and Specific Serotonergic Antidepressant (NaSSA; Ce
- [11.22]-CMP141 Trihexyphenidyl (Benzhexol) Hydrochloride IP — First-Generation (Typical) Butyrophenone Antipsychotic (Potent Do
